CHARM 2: Chemotherapy for ablation and resolution of mucinous pancreatic cysts: a prospective, randomized, double-blind, multi-center clinical trial
魅力 2:化疗消融和解决粘液性胰腺囊肿:一项前瞻性、随机、双盲、多中心临床试验
基本信息
- 批准号:9750284
- 负责人:
- 金额:$ 41.34万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-08-01 至 2023-07-31
- 项目状态:已结题
- 来源:
- 关键词:Abdominal PainAblationAdmixtureAdultAdverse eventAlcohol consumptionAspirate substanceCancer EtiologyCaringCessation of lifeClinicalCombination Drug TherapyCystCystic LesionDiagnosisDiagnostic radiologic examinationDouble-Blind MethodDyesEarly InterventionEndoscopic UltrasonographyEndoscopyEpidemicEthanolExcisionExtravasationFundingGastroenterologyGeneral PopulationHospitalizationImageImaging TechniquesIn complete remissionIncidenceInfusion proceduresInjectionsInterventionInvestigationIrrigationLesionLinkMagnetic Resonance ImagingMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of pancreasMethodsModalityMucinousMulti-Institutional Clinical TrialMulticenter TrialsNeedlesNewly DiagnosedOperative Surgical ProceduresPaclitaxelPancreatectomyPancreatic CystPancreatic cystic neoplasiaPatientsPharmacologyPilot ProjectsPremalignantPrevalenceProceduresPublic HealthPublishingQualifyingRandomizedRandomized Controlled TrialsRelative RisksResearchResolutionRiskSafetySalineSurgical OncologyTestingTimeTissuesUnited StatesWeightX-Ray Computed Tomographyacute pancreatitisadverse event riskaging populationbasechemotherapeutic agentchemotherapyclinically significantcostdesigneffective therapyexperiencefollow-upgemcitabinehigh riskmalignant breast neoplasmmortalitymultidisciplinarynovelprospectivepublic health relevancerandomized trialstandard of caresuccesstreatment grouptreatment strategytrial comparingtwo-arm study
项目摘要
Pre-malignant pancreatic cysts that are difficult to characterize and treat are increasingly
discovered in the US over the last two decades due to advances in imaging and an aging
population. With the incidence of highly lethal pancreatic cancer rising in the US, intervening on
pancreatic cysts with malignant potential in a safe and effective way is a major public health
concern. While patients have been historically limited to radiographic surveillance or potentially
hazardous surgery as undesirable methods of managing these cysts, endoscopic ultrasound
guided fine needle injection (EUS-FNI) has emerged as a less-invasive, safe and effective
method of early intervention. For EUS-guided treatment of pancreatic cysts today, care typically
includes lavage with ethanol. However, experts agree that adverse events (AEs) observed
during treatment are due to ethanol use. Recently, based on the safety concerns surrounding
ethanol use, as well as the promising treatment findings linked to the infusion of paclitaxel, our
team created an ethanol-free (EF), combination chemotherapy treatment consisting of an
admixture—paclitaxel and gemcitabine—specifically designed to target pancreatic cystic
neoplasia by EUS-guided injection. Our team completed testing of this novel treatment strategy
in 2017 as a preliminary randomized trial, showing that EF lavage (i.e., saline) with combination
chemotherapy was as effective, and far safer, than the same chemotherapy treatment with the
inclusion of ethanol lavage (EL). In this proposal, our aim is increase the scale of our pilot study,
conducting a large and definitive multi-center trial that will be the first funded RCT to compare
treatment with EL to ethanol-free (EF) treatment with combination infusion of chemotherapeutic
agents. All subjects will have qualifying cystic lesions aspirated and evacuated, and undergo a
follow-up procedure at 3 months and final imaging at 12 months. We will randomly assign 100
adult patients with pancreatic cysts to two study arms: (1) Ethanol lavage (EL): EL, followed by
infusion of a paclitaxel-gemcitabine admixture, or (2) Ethanol Free (EF): saline lavage, followed
by infusion of the same paclitaxel-gemcitabine admixture. We hypothesize that EF treatment will
result in significantly fewer adverse events and will have complete cyst ablation resolution rates
that are not inferior to EL treatment. If the EF intervention proves to be non-inferior to, and
significantly safer than, treatment with EL, it will validate EUS-FNI as a viable treatment modality
for intervening on pre-malignant cysts and will change the standard of care for pancreatic cyst
management. Critically, if EF treatment is successful, it may alter the treatment decisions that
patients make and change the treatment options that centers of excellence offer.
胰腺癌前病变的特征和治疗都很困难,
在过去的二十年里,由于成像技术的进步和衰老,
人口随着美国高致命性胰腺癌发病率的上升,
胰腺囊肿具有恶性潜能,以安全有效的方式治疗是一项重大的公共卫生
关心虽然患者在历史上一直局限于放射学监测或潜在的
危险的手术作为不可取的方法管理这些囊肿,内镜超声
引导细针注射(EUS-FNI)已成为一种微创,安全和有效的
早期干预的方法。目前,对于胰腺囊肿的EUS引导治疗,
包括用乙醇灌洗。然而,专家一致认为,观察到的不良事件(AE)
在治疗过程中,由于使用乙醇。最近,基于对周围安全问题的担忧,
乙醇的使用,以及与紫杉醇输注相关的有希望的治疗发现,我们
研究小组创造了一种无乙醇(EF)的联合化疗疗法,
紫杉醇和吉西他滨混合物-专为靶向胰腺囊性病变而设计
通过EUS引导注射的瘤形成。我们的团队完成了对这种新型治疗策略的测试
在2017年作为初步随机试验,显示EF灌洗(即,生理盐水)
化疗是有效的,而且比同样的化疗更安全,
包括乙醇灌洗(EL)。在这项建议中,我们的目标是扩大我们试点研究的规模,
进行一项大型和确定性的多中心试验,这将是第一个资助的随机对照试验,
EL治疗至无乙醇(EF)治疗联合化疗药物输注
剂.所有受试者将进行合格的囊性病变抽吸和清除,并接受
3个月时进行随访,12个月时进行最终成像。我们将随机分配100名
成人胰腺囊肿患者分为两个研究组:(1)乙醇灌洗(EL):EL,然后
输注紫杉醇-吉西他滨混合物,或(2)无乙醇(EF):盐水灌洗,然后
通过输注相同的紫杉醇-吉西他滨混合物。我们假设EF治疗将
导致不良事件显著减少,并将具有完全的囊肿消融解决率
不低于EL治疗。如果EF干预被证明不劣于,且
它比EL治疗安全得多,将验证EUS-FNI作为一种可行的治疗方式
用于干预癌前囊肿,并将改变胰腺囊肿的护理标准
管理重要的是,如果EF治疗成功,它可能会改变治疗决定,
患者可以选择和改变卓越中心提供的治疗方案。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
John M DeWitt其他文献
John M DeWitt的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('John M DeWitt', 18)}}的其他基金
CHARM 2: Chemotherapy for ablation and resolution of mucinous pancreatic cysts: a prospective, randomized, double-blind, multi-center clinical trial
魅力 2:化疗消融和解决粘液性胰腺囊肿:一项前瞻性、随机、双盲、多中心临床试验
- 批准号:
10478007 - 财政年份:2018
- 资助金额:
$ 41.34万 - 项目类别:
CHARM 2: Chemotherapy for ablation and resolution of mucinous pancreatic cysts: a prospective, randomized, double-blind, multi-center clinical trial
魅力 2:化疗消融和解决粘液性胰腺囊肿:一项前瞻性、随机、双盲、多中心临床试验
- 批准号:
10002201 - 财政年份:2018
- 资助金额:
$ 41.34万 - 项目类别:
相似海外基金
Targeted ablation of cerebral atherosclerosis using supramolecular self-assembly
利用超分子自组装靶向消融脑动脉粥样硬化
- 批准号:
24K21101 - 财政年份:2024
- 资助金额:
$ 41.34万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
心房細動に対するPulsed Field Ablationの組織創傷治癒過程を明らかにする網羅的研究
阐明房颤脉冲场消融组织伤口愈合过程的综合研究
- 批准号:
24K11201 - 财政年份:2024
- 资助金额:
$ 41.34万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
遅延造影心臓MRIによる心房細動Ablation冷却効果の比較:28 vs. 31 mm Cryoballoon
使用延迟对比增强心脏 MRI 比较房颤消融冷却效果:28 毫米与 31 毫米 Cryoballoon
- 批准号:
24K11281 - 财政年份:2024
- 资助金额:
$ 41.34万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
InSPACE-VT_Development and Validation of Virtual Pace Mapping to Guide Catheter Ablation of Ventricular Tachycardia
InSPACE-VT_虚拟起搏测绘的开发和验证以指导室性心动过速导管消融
- 批准号:
EP/Z001145/1 - 财政年份:2024
- 资助金额:
$ 41.34万 - 项目类别:
Fellowship
CAREER: Heat Penetration Depth and Direction Control with Closed-Loop Device for Precision Ablation
职业:利用闭环装置控制热穿透深度和方向,实现精确烧蚀
- 批准号:
2338890 - 财政年份:2024
- 资助金额:
$ 41.34万 - 项目类别:
Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
- 批准号:
2334777 - 财政年份:2024
- 资助金额:
$ 41.34万 - 项目类别:
Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
- 批准号:
2334775 - 财政年份:2024
- 资助金额:
$ 41.34万 - 项目类别:
Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
- 批准号:
2334776 - 财政年份:2024
- 资助金额:
$ 41.34万 - 项目类别:
Continuing Grant
Cryo laser-ablation system (157+193nm) with 'triple-quad' plasma mass spectrometer, Cryo-LA-ICPMS/MS
带有“三重四极杆”等离子体质谱仪、Cryo-LA-ICPMS/MS 的冷冻激光烧蚀系统 (157 193nm)
- 批准号:
515081333 - 财政年份:2023
- 资助金额:
$ 41.34万 - 项目类别:
Major Research Instrumentation
MRI: Acquisition of a Laser Ablation - Inductively Coupled Plasma - Triple Quadrupole - Mass Spectrometer (LA-ICP-QQQ-MS) System For Research and Education
MRI:获取用于研究和教育的激光烧蚀 - 电感耦合等离子体 - 三重四极杆 - 质谱仪 (LA-ICP-MS/MS) 系统
- 批准号:
2320040 - 财政年份:2023
- 资助金额:
$ 41.34万 - 项目类别:
Standard Grant